Constance M. Cultraro

1.2k total citations
30 papers, 510 citations indexed

About

Constance M. Cultraro is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Constance M. Cultraro has authored 30 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Constance M. Cultraro's work include Lung Cancer Treatments and Mutations (12 papers), Peptidase Inhibition and Analysis (4 papers) and Ubiquitin and proteasome pathways (4 papers). Constance M. Cultraro is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Peptidase Inhibition and Analysis (4 papers) and Ubiquitin and proteasome pathways (4 papers). Constance M. Cultraro collaborates with scholars based in United States, Belgium and Italy. Constance M. Cultraro's co-authors include Shoshana Segal, Tamar Bino, Udayan Guha, Harvey B. Pollard, Anat Shirvan, A. Lee Burns, Tapan K. Maity, Meera Srivastava, Abhilash Venugopalan and Xu Zhang and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Constance M. Cultraro

29 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Constance M. Cultraro United States	14	381	166	109	65	49	30	510
Vivien N. Jacobs United Kingdom	11	290 0.8×	194 1.2×	67 0.6×	53 0.8×	50 1.0×	18	504
Matias Casás‐Selves United States	8	350 0.9×	175 1.1×	71 0.7×	126 1.9×	75 1.5×	9	549
Alexey V. Bazarov United States	10	333 0.9×	266 1.6×	91 0.8×	117 1.8×	31 0.6×	12	525
Elisabeth Llonch Switzerland	2	509 1.3×	214 1.3×	128 1.2×	93 1.4×	40 0.8×	2	651
Jiahuai Tan United States	8	548 1.4×	165 1.0×	48 0.4×	95 1.5×	41 0.8×	16	687
Søren M. Johnson United States	5	192 0.5×	174 1.0×	101 0.9×	47 0.7×	59 1.2×	5	391
Rebecca L. Lynch United States	4	452 1.2×	143 0.9×	98 0.9×	88 1.4×	38 0.8×	4	615
Katherine R. Singleton United States	11	497 1.3×	209 1.3×	190 1.7×	135 2.1×	38 0.8×	16	652
Scott Ackler United States	8	472 1.2×	233 1.4×	45 0.4×	38 0.6×	75 1.5×	10	625
Elizabeth Moskatel United States	3	318 0.8×	96 0.6×	57 0.5×	44 0.7×	67 1.4×	4	389

Countries citing papers authored by Constance M. Cultraro

Since Specialization

Citations

This map shows the geographic impact of Constance M. Cultraro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constance M. Cultraro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constance M. Cultraro more than expected).

Fields of papers citing papers by Constance M. Cultraro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constance M. Cultraro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constance M. Cultraro. The network helps show where Constance M. Cultraro may publish in the future.

Co-authorship network of co-authors of Constance M. Cultraro

This figure shows the co-authorship network connecting the top 25 collaborators of Constance M. Cultraro. A scholar is included among the top collaborators of Constance M. Cultraro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constance M. Cultraro. Constance M. Cultraro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Hanyang, Constance M. Cultraro, Daniel Feliciano, et al.. (2026). PLIN5 phosphorylation orchestrates mitochondria lipid-droplet coupling to control hepatic lipid flux and steatosis. Nature Metabolism. 8(3). 587–603.

Roper, Nitin, Rajaâ El Meskini, Tapan K. Maity, et al.. (2024). Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer Research Communications. 4(2). 337–348. 1 indexed citations

Cunningham, Rory P., Constance M. Cultraro, Adam Harned, et al.. (2024). A spatial map of hepatic mitochondria uncovers functional heterogeneity shaped by nutrient-sensing signaling. Nature Communications. 15(1). 1799–1799. 28 indexed citations

Maity, Tapan K., Eun Young Kim, Constance M. Cultraro, et al.. (2023). Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance. Cancers. 15(8). 2263–2263. 8 indexed citations

Zhang, Xu, Tapan K. Maity, Karen Ross, et al.. (2021). Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance. Cancer Research. 81(11). 3051–3066. 43 indexed citations

Venugopalan, Abhilash, et al.. (2021). SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. Oncogene. 40(18). 3331–3346. 7 indexed citations

Qi, Yue, Tapan K. Maity, Constance M. Cultraro, et al.. (2021). Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. Molecular & Cellular Proteomics. 20. 100136–100136. 19 indexed citations

Xi, Liqiang, Constance M. Cultraro, Fengcai Wei, et al.. (2019). P1.01-27 Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 14(10). S366–S366. 1 indexed citations

Kim, Chul, Nitin Roper, Chuong D. Hoang, et al.. (2018). Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.. Journal of Clinical Oncology. 36(15_suppl). e21080–e21080. 5 indexed citations

10.

Xi, Liqiang, Constance M. Cultraro, Nitin Roper, et al.. (2018). P1.01-46 Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S478–S478. 2 indexed citations

11.

Zhang, Xu, Tapan K. Maity, Manoj Kumar Kashyap, et al.. (2017). Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Molecular & Cellular Proteomics. 16(5). 891–910. 37 indexed citations

12.

Venugopalan, Abhilash, Min-Jung Lee, Gang Niu, et al.. (2016). EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget. 7(34). 54137–54156. 28 indexed citations

13.

Maity, Tapan K., Abhilash Venugopalan, Ilona Linnoila, et al.. (2015). Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma. Cancer Discovery. 5(5). 534–549. 51 indexed citations

14.

Zingone, Adriana, Constance M. Cultraro, Camilla Bean, et al.. (2010). Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia. 24(6). 1171–1178. 15 indexed citations

15.

Cultraro, Constance M., Tamar Bino, & Shoshana Segal. (1997). Function of the c-Myc Antagonist Mad1 during a Molecular Switch from Proliferation to Differentiation. Molecular and Cellular Biology. 17(5). 2353–2359. 61 indexed citations

16.

Casalini, Patrizia, et al.. (1997). Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. International Journal of Cancer. 72(4). 631–636. 18 indexed citations

17.

Cultraro, Constance M., Tamar Bino, & Shoshana Segal. (1997). Regulated Expression and Function of the c-Myc Antagonist, Mad1, During a Molecular Switch from Proliferation to Differentiation. Current topics in microbiology and immunology. 224. 149–158. 6 indexed citations

18.

Cultraro, Constance M., et al.. (1996). c-Myc inactivation by mutant max alters growth and morphology of NCI-H-630 colon cancer cells. Journal of Cellular Physiology. 169(1). 200–208. 7 indexed citations

19.

Bar-Ner, M, et al.. (1992). Regions within the c-Myc protein that are necessary for transformation are also required for inhibition of differentiation of murine erythroleukemia cells.. PubMed. 3(3). 183–90. 16 indexed citations

20.

Shirvan, Anat, et al.. (1991). Alternative splicing of human synexin mRNA in brain, cardiac, and skeletal muscle alters the unique N-terminal domain.. Journal of Biological Chemistry. 266(5). 3228–3232. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact